Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NAVB,
Now at 2.29.
Could be a great buy as a tax loss selling candidate with PDUFA coming in April.I have it at much higher prices.
It is a heavily Shorted stock,but institutions now own 23% of shares.
Also,this was posted on the NAVB old timers board:
There are now 10 institutions with 500k or more shares...
...and EVERY one of them increased their positions during the last quarter (4 of them by 600,000 shares or more). I'm really impressed by the addition of Nomura Holdings which bought 2 million shares to establish their position.
This is as of of 9/30...which was AFTER the news of the FDA delay and BEFORE the expeditious and successful resubmission of the NDA.
Obviously there are a number of professionals who believe in our company's prospects.
http://www.nasdaq.com/symbol/navb/institutional-holdings
BFCF,
Do you have any target price?
This guy "gizwick" on Silicon Investor is pretty bullish
"BFCF up 23% today headed towards book value of $4.00. Talk about a value story, this is it. The company owns 53 and 54% of BBX and BXG. BFCF just landed a cash purchase of the rest of BXG that it doesn't own. More offers are probably going to come for BGX as it is undervalued at a $10.00 cash price offer. BBX will probably be the next company to be bought out at a present book value of over $16.00. GLTA"
Tis is what he posted on 10/5/12.He nailed the buy prediction,and thought stock could be 1.75 in early 2013.
"Will take a few thousand more shares of BFCF. Book value of over $2.00 selling for $.81. The company owns 54% of BXG and has over $16.00 per share cash in the bank. They are merging with BXG and buying BXG on the cheap. When the stock market listing happens in early 2013 and everything is said and done present BFCF shares will be worth over $1.75. A double from here. BFCF will become a mini Berkshire Hathaway. Ceo has done well with previous stakes in Benihana ( went private at $16.00) and Bank Atlantic that was sold to BB&T. They now have a huge cash hoard to fund future investments. Patience will be rewarded handsomely. Now that is what I call a value opportunity."
ARNA,
This seems to be a rumor,but stock is moving higher on it.
From IV:
"DEA says Belviq will be a schedule IV drug!!! Terrific news.
Will be posted on DEA website soon. "
Manny
BFCF,
There were 50,000 shares on the Ask.
Now only 2,000 shares remain.
I can't believe that there is no message activity on IHub.
Manny
VHC,
Looks like more patents coming.
Posted by flyers on IV,as part of a bigger post:
I can't copy the image,so I am posting the url.
http://www.investorvillage.com/smbd.asp?mb=8852&mn=34129&pt=msg&mid=12317268
Manny
VHC,
It would be nice if there is more institutional buying coming next week,based on these thoughts,found on IV:
Re: 500,000 share trade at $31.0493 posted at 16:48
Interesting post on the Yahoo board from "Nicklaus999", who have proven in the past to be an experienced, knowledgeable trader:
That was a legit insitutiutional buy
By nicklaus999 . 53 minutes ago
It explains the reversal. The shorts are in so much trouble. That was without a doubt a long purchase and I am very confident it was a new position being initiated. My guess is they are probably not done. Where there is one institution there are surely more to follow. My advice, get long NOW. I'd be buying big in after hrs. Institutional money that was sitting on the sidelines waiting for the verdict is starting to buy and that means HUGE trouble for shorts. This is so funny. Option will probably rocket too.
By nicklaus999 . 26 seconds ago .
The other thing of note is this. Whatever mm had the order he could have put it up right after the close, but he didn't. He waited almost an hour to print the trade. He printed it out at essentially 4:50 pm est. No reason to do that. My guess is he has been working with the shorts and wanted to wait til most of the pros went home before he put up the trade because he knew that was a huge buy order from a fund. If that was a typical insitutional print in a standard large cap stock that trade would have been printed between 4pm and 4:15 pm est. He printed it late because you wanted to hide it. Either he or his associates/bigger clients (hedgies) are short. This is the reason the stock didn't close sub 30 today. We found a real buyer finally and I'm sure he'll be back or his friends will be here shortly.
GV,
I also added at 1.46.
There are people I follow, that think we are at least near a short term bottom.
Manny
DVAX,
Now at 2.16,up .18 from after-hours yesterday.
Ten day average volume is 5,832,990.
Volume in pre-market 6,675,000.
Manny
DVAX,
Now at 2.16,up .18 from after-hours yesterday.
Ten day average volume is 5,832,990.
Volume in pre-market 6,675,000.
Manny
DVAX,
Jeffries cuts target price to 5 from 6.
I'll take it.
Manny
DVAX,
Institutions own 85% of DVAX.
Insiders own 6.61%.
http://finance.yahoo.com/q/ks?s=DVAX+Key+Statistics
% Held by Insiders1: 6.61%
% Held by Institutions1: 85.00%
Manny
DVAX,
Institutions own 85% of DVAX.
Insiders own 6.61%.
http://finance.yahoo.com/q/ks?s=DVAX+Key+Statistics
% Held by Insiders1: 6.61%
% Held by Institutions1: 85.00%
Manny
DVAX,
Over 2 now.
"Some of the panel members who voted against the vaccine's safety said larger and longer studies should be conducted before the vaccine is approved, but others suggested it might be done after approval. The FDA will make the final decision."
UPDATE: FDA Panel Calls for More Data on Dynavax Hepatitis B Vaccine
Print
Alert
Dynavax Technologies Corp. (MM) (NASDAQ:DVAX)
Intraday Stock Chart
Today : Thursday 15 November 2012
Click Here for more Dynavax Technologies Corp. (MM) Charts.
--FDA panel says more safety information is needed on Dynavax's hepatitis B vaccine
--Panel says vaccine appears effective
--FDA to make final approval decision
(Updates with additional information on proposed vaccine starting in fifth paragraph.)
By Jennifer Corbett Dooren
WASHINGTON--A federal advisory panel Thursday said more safety information is needed for a proposed hepatitis B vaccine being developed by Dynavax Technologies Corp. (DVAX), which could delay the vaccine's approval.
The company is seeking Food and Drug Administration approval for use of the vaccine, called Heplisav, in adults who are 18 to 70 years old.
Dynavax's vaccine was reviewed by the FDA's vaccines advisory committee, which is made up of non-FDA medical experts. The panel voted 8-5 against a question that asked if the company submitted enough data to support the vaccine's safety. One person abstained from voting. However, the same panel voted 13-1 saying that data submitted by the company supported the vaccine's effectiveness.
Some of the panel members who voted against the vaccine's safety said larger and longer studies should be conducted before the vaccine is approved, but others suggested it might be done after approval. The FDA will make the final decision.
There are already hepatitis B vaccines on the market from GlaxoSmithKline PLC (GSK, GSK.LN) and Merck & Co. (MRK), according to the FDA.
Heplisav is designed to be administered twice in a one-month period, while the other vaccines are given to adults as a three-dose series during a six-month time period, which the company said has the potential to improve vaccination rates and protection against hepatitis B in adults. The vaccine also contains a new ingredient, called an adjuvant, that is designed to boost the body's immune response to a vaccine. Because of the new ingredient, some advisory committee panel members said additional safety information is needed.
The vaccine's safety was studied in about 5,800 patients, but none of the studies lasted for more than a year, according to the FDA. About 1,400 study participants received a GlaxoSmithKline vaccine as a comparison. Agency reviewers said there were no major safety differences between the vaccines.
"There's a lot of enthusiasm around the table from the yes and no voters that this is a very promising vaccine approach," said Robert Daum, the panel chairman and doctor at the University of Chicago.
Hepatitis B is a liver disease caused by infection with the hepatitis B virus, which is most often spread through sexual contact or the sharing of needles or other drug-injection equipment. Since 1992, babies and toddlers in the U.S. have been routinely vaccinated against hepatitis B, but many adults remain unvaccinated. Last year, a federal vaccine advisory panel recommended certain adults with diabetes receive the hepatitis B vaccine.
Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
DVAX,
The current 1.75 price seems ridiculous.
Why can't a big pharma company buy out DVAX,because the drug is effective 13 to 1,but needs some more safety studies.
Thoughts?
Manny
VHC,
Looks like no appeal threat from Apple until court signs judgement around or after december 20th.
Hopefully stock will now be stable or higher on positive news.
From a poster on IV:
Appeals from Judgments in Federal Court
You are correct that the time for giving Notice of Appeal does not begin until after the Court signs the Judgment. Different States and Jurisdictions use different terms for the same thing. Basically the jury renders it's verdict on a form called the Jury Charge by answering questions. Once the verdict is accepted by the Court as being complete, the attorneys then file all kinds of different motions addressed to the Court ranging from Motions for New Trial; Motions for Judgment Notwithstanding the Juries Verdict; Motions for Remittitur, etc. (read the Federal Rules of Civil Procedure under post verdict motions to get an idea of the range of motions that can be filed).
The Court considers all the motions either by submission or in hearing argument of counsel (in our case argument on Dec. 20). Thereafter, the Court will render it's written Judgment. The Judgment can be announced orally in open court by the judge says something like, "I'll let you know my decision". Eventually, the Court will reduce his findings on the motions to writing and then sign a formal written Judgment. The date of the filing of the signed Judgment usually triggers all the time limits and procedure for perfecting an appeal. The Judgment of the Court is not final until all appeals are exhausted or no appeal is perfected.
Also, everyone keep in mind that there is such a thing as the appeal court dismissing frivolous appeals. It's pretty rare, but sometimes it can happen. HOWEVER, there are scores of reasons for appeal which are valid. ranging from alleging errors in the court's charge, harmful and erroneous evidentiary rulings, and many others. Usually the winning side's stockholders laugh at some of the appeal points, but believe me there are many legal reasons for a reversal no matter how fair a trial we think Apple got and however frivolous we thought of their evidence and case.
Lastly, as most of the board's members know, the Federal Courts in the Eastern District of Texas are generally known among legal circles as the "rocket docket". Passage of time has proven, it's not a rocket docket but it is faster than most. I have seen some judges take a year to sign a judgment, but knowing this court, I would suspect it will not take long. However, we must consider that the hearing is only 5 days before Christmas and considering the Holiday season's lenght we might not know what his judgment is for a while.
Lastly, appeal is a matter of right for Apple. They may or may not appeal, but they have the right and they don't have to get permission to appeal for cause.
Best of luck to all and I am long this stock.
g hors
ACFN,
This stock should be a nice buy when this market starts moving back up.I am in already at a higher price.
The company is also paying a dividend:
"--Acorn Energy , Inc . ( NASDAQ : ACFN ) , an energy technology holding company , today announced that its Board of Directors has approved a dividend of $ 0 . 035 per share to be paid on December 3 , 2012 to common stockholders of record on November 15 , 2012 . The dividend follows Acorn Energy ' s policy to pay a regular quarterly per share dividend of $ . 035 per quarter ."
Insider buy yesterday by CEO of 5,000 shares at average 7.659.
He now owns over 880,000 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8556129
Director buys 1,000 shares at 7.7.He now owns 32,000 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8554807
Manny
ACFN,
This stock should be a nice buy when this market starts moving back up.I am in already at a higher price.
The company is also paying a dividend:
"--Acorn Energy , Inc . ( NASDAQ : ACFN ) , an energy technology holding company , today announced that its Board of Directors has approved a dividend of $ 0 . 035 per share to be paid on December 3 , 2012 to common stockholders of record on November 15 , 2012 . The dividend follows Acorn Energy ' s policy to pay a regular quarterly per share dividend of $ . 035 per quarter ."
Insider buy yesterday by CEO of 5,000 shares at average 7.659.
He now owns over 880,000 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8556129
Director buys 1,000 shares at 7.7.He now owns 32,000 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8554807
Manny
VHC,
A post by floydrocks, one of the sharpest people on the IV VHC thread:
Apple / Next Steps
It is interesting how many people are fixated on Apple and the "next step" for VirnetX.
Does Apple appeal?
Does Apple settle?
What is the royalty rate?
What about the ITC case - how will Apple try and defend itself there?
Will there be injunctions on Apple products?
I receive a lot of these questions privately. None of us really knows how it will all play out - exactly. That's why I look at the big picture. Apple is only one stepping stone in the long-term business model. VHC just did what they had to do - beat Apple handily. Now they move on to the next drive of the game... Apple is not all there is to the company's business plan. They are just a part of it.
I spoke with a good friend last night and told him of a conversation I had with someone a week before the trial. The person basically asked me what I thought Apple's strategy would be. My response was this: Apple will say they aren't infringing, they didn't know they were infringing, and even if they are, it's not worth much. They would deflect as much as possible. In other words, they have no defense because they are using the technology.
So, it was not a shock to read about the video compilation of Apple engineers saying they never looked at the patents, they never bothered to look, and they still don't know if they are using VHC technology. And then Apple's attorneys and experts get up there and say, well, even if we are infringing, it's only worth 9 million. And if Apple has to, they they can change over to a non-infringing alternative quite easily, for a mere $3.6 million, and all within the span of a month. I can't wait to see them called on that bluff.
My point is, Apple had no defense. "Directly" was a non-issue, despite the shorts hanging their hats on this. Kiuchi was a non-issue, despite the shorts saying it is a problem. Ignorance on the part of their engineers is not an excuse to use patents without licensing. So if Apple appeals, I say bring it. They still have no defense. IMHO, no matter how things play out going forward, so much of the risk has been removed. The short-term volatility, as we stated before, will continue. Embrace it.
While most are staying focused on the next step with Apple, I am not. It is VHC that has the upper hand now, not Apple. I believe things will continue to fall into place and am looking for many more developments besides Apple's next move. Shorts can head fake all they want, but at the end of the day, it's all about execution. And KL and VHC are executing their plan every step of the way.
I am out for now.
This company does not seem trustworthy with all their flubs.
I will buy only if there is significant news on Anatabloc.
Manny
VHC,
From IV:
Peter B. Cannell & Co
VHC is now its 8th largest holding after adding 197,000 additional shares in the latest reporting period (09/30/12).
Peter B. Connell Top Holdings (link)
Company Class Value of Shares ($1,000s) Change in Value Change (%) Shares Held
CELGENE CORP COM 87,403,034 (11,076,455) (11.25) 1,225,849
BROOKFIELD ASSET MGMT INC CL A LTD VT SH 81,533,111 (605,651) (0.74) 2,402,980
APPLE INC COM 69,624,106 (5,322,112) (7.1) 129,473
QUALCOMM INC COM 61,474,788 12,794,696 26.28 1,013,265
SLM CORP COM 60,765,793 (60,287) (0.1) 3,608,420
PERKINELMER INC COM 55,434,492 20,759,756 59.87 1,807,450
TRONOX LTD SHS CL A 54,434,047 54,434,047 New 2,955,160
VIRNETX HLDG CORP COM 54,408,191 7,191,157 15.23 1,494,320
Post Unavailable
Additional Information
VHC,
now we wait for the royalty rate that Judge Davis puts on all the infringing Apple products.
yesterday only hours after the ruling,VHC filed new infringement claims against the IPhone 5.
This is a keeper for me with huge forward potential.
Manny
VHC,
Up 4.21 to 30.50.
VHC wins. Apple found guilty of all claims. All patent claims valid. Damages in the amount of $386 million to be paid to VirnetX.
Manny
VHC,
Up 4.21 to 30.50.
VHC wins. Apple found guilty of all claims. All patent claims valid. Damages in the amount of $386 million to be paid to VirnetX.
Manny
VHC,
EricVonCartman of IV, posted this video a day early,but shows his confidence in victory.ABSOLUTELY BRILLIANT.
For those of you not on IV VHC board,you will not recognize many of the names mentioned,but you will get the idea.
Nuke John,
What do you think about these reports,and how it would affect the stock price?
TIA,
Manny
Re: Star Scientific Announces Successful First Look at the "Flint" CRP Human Study and Provides Updated Report on ASAP Human Thyroid Study
After one month of supplementation, CRP levels dropped in 26% of the subjects with diabetes, compared with a drop in CRP levels in 12% of the general trial population of subjects who did not have diabetes.
Is this news good enough?
Manny
What will it take for you to think otherwise,now that the stock price is close to even.
Unless it is all Anatabloc and cream.
Manny
They just went trough around 110,000 share sell on the Ask at 3.20 like it was butter.
Looks like we may close positive for the day.
Manny
VHC,
Posted by jstevenbaker of IV:
Checklist
In this EDTX case with HJD presiding, Apple has attempted to:
1. Dismiss suit due to lack of standing absent SAIC - FAIL
2. Delay trial/conclusion with stay pending re-exams - FAIL
3. Strike technical expert (Dr Jones') remarks implicating infringement - FAIL
4. Invalidate VHC patents with Schulzrinne prior art - FAIL
5. Quash VirnetX's Doctrine of Equivalence amendment - FAIL
6. Limit exposure through striking damages expert (Weinstein's) opinions - FAIL
It's obvious that the contested matters blew up in Apple's face. What could Apple expect to go differently at trial?
I just added 33% to my position at 2.84.
It looks like Anatabloc will be the big consideration from now on.
Manny
5 million settlement,as per my Schwab.Can't post because of copyright considerations. EOM Manny
I think you are looking for attention for the stock you are posting endlessly about.
I bet you didn't even read the presentation.
Manny
VHC,
Stay denied.From IV:
It's officially filed, "Discussed reexamination status and lack of outcome predictability. Court DENIED Defendants’ Motion to Stay Pending Ongoing Reexamination"
It's official (not that Floyd's word isn't anything but), "Court DENIED Defendants’ Motion to Stay Pending Ongoing Reexamination Proceedings (Docket #477 - page 2)."
Court requested arguments from the parties on Defendants’ Motion to Stay Pending
Ongoing Reexamination Proceedings (Docket #477).
Michael Stadnick for Cisco presented arguments. Discussed proceedings at
USPTO. Discussed prior case against Microsoft. Discussed claim status for each
patent at the USPTO. Discussed legal standards. Discussed prejudice issues.
Discussed simplification of case and current litigation status.
Danny Williams for Apple presented additional arguments. Discussed status of
patents asserted against Apple at USPTO.
Doug Cawley presented arguments for Plaintiff. Discussed examples of cases
litigated while USPTO proceedings pending and unpredictability of final USPTO
actions. Discussed Soverain factors. Discussed prejudice issues. Court inquired
regarding litigation timeframe as opposed to USPTO proceedings. Mr. Cawley
responded. Discussed simplification issues. Court inquired regarding claim scope
in reexamination proceedings. Mr. Cawley responded.
Mr. Stadnick responded for Cisco. Discussed examples provided by Plaintiff and
differences in this case. Discussed priority of litigation and USPTO actions.
Court requested arguments from the parties on Defendants’ Motion to Stay Pending
Ongoing Reexamination Proceedings (Docket #477).
Michael Stadnick for Cisco presented arguments. Discussed proceedings at
USPTO. Discussed prior case against Microsoft. Discussed claim status for each
patent at the USPTO. Discussed legal standards. Discussed prejudice issues.
Discussed simplification of case and current litigation status.
Danny Williams for Apple presented additional arguments. Discussed status of
patents asserted against Apple at USPTO.
Doug Cawley presented arguments for Plaintiff. Discussed examples of cases
litigated while USPTO proceedings pending and unpredictability of final USPTO
actions. Discussed Soverain factors. Discussed prejudice issues. Court inquired
regarding litigation timeframe as opposed to USPTO proceedings. Mr. Cawley
responded. Discussed simplification issues. Court inquired regarding claim scope
in reexamination proceedings. Mr. Cawley responded.
Mr. Stadnick responded for Cisco. Discussed examples provided by Plaintiff and
differences in this case. Discussed priority of litigation and USPTO actions.
Mr. Williams responded for Apple. Discussed example of reexamination in prior
Microsoft case. Discussed current status at USPTO.
Mr. Cawley replied for Plaintiff.
Discussed reexamination status and lack of
outcome predictability.
Court DENIED Defendants’ Motion to Stay Pending Ongoing Reexamination
Proceedings (Docket #477).
VHC,
Stay denied.From IV:
It's officially filed, "Discussed reexamination status and lack of outcome predictability. Court DENIED Defendants’ Motion to Stay Pending Ongoing Reexamination"
It's official (not that Floyd's word isn't anything but), "Court DENIED Defendants’ Motion to Stay Pending Ongoing Reexamination Proceedings (Docket #477 - page 2)."
Court requested arguments from the parties on Defendants’ Motion to Stay Pending
Ongoing Reexamination Proceedings (Docket #477).
Michael Stadnick for Cisco presented arguments. Discussed proceedings at
USPTO. Discussed prior case against Microsoft. Discussed claim status for each
patent at the USPTO. Discussed legal standards. Discussed prejudice issues.
Discussed simplification of case and current litigation status.
Danny Williams for Apple presented additional arguments. Discussed status of
patents asserted against Apple at USPTO.
Doug Cawley presented arguments for Plaintiff. Discussed examples of cases
litigated while USPTO proceedings pending and unpredictability of final USPTO
actions. Discussed Soverain factors. Discussed prejudice issues. Court inquired
regarding litigation timeframe as opposed to USPTO proceedings. Mr. Cawley
responded. Discussed simplification issues. Court inquired regarding claim scope
in reexamination proceedings. Mr. Cawley responded.
Mr. Stadnick responded for Cisco. Discussed examples provided by Plaintiff and
differences in this case. Discussed priority of litigation and USPTO actions.
Court requested arguments from the parties on Defendants’ Motion to Stay Pending
Ongoing Reexamination Proceedings (Docket #477).
Michael Stadnick for Cisco presented arguments. Discussed proceedings at
USPTO. Discussed prior case against Microsoft. Discussed claim status for each
patent at the USPTO. Discussed legal standards. Discussed prejudice issues.
Discussed simplification of case and current litigation status.
Danny Williams for Apple presented additional arguments. Discussed status of
patents asserted against Apple at USPTO.
Doug Cawley presented arguments for Plaintiff. Discussed examples of cases
litigated while USPTO proceedings pending and unpredictability of final USPTO
actions. Discussed Soverain factors. Discussed prejudice issues. Court inquired
regarding litigation timeframe as opposed to USPTO proceedings. Mr. Cawley
responded. Discussed simplification issues. Court inquired regarding claim scope
in reexamination proceedings. Mr. Cawley responded.
Mr. Stadnick responded for Cisco. Discussed examples provided by Plaintiff and
differences in this case. Discussed priority of litigation and USPTO actions.
Mr. Williams responded for Apple. Discussed example of reexamination in prior
Microsoft case. Discussed current status at USPTO.
Mr. Cawley replied for Plaintiff.
Discussed reexamination status and lack of
outcome predictability.
Court DENIED Defendants’ Motion to Stay Pending Ongoing Reexamination
Proceedings (Docket #477).
SCMP,
The "three Insiders" are the same entity.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8513396
Selling 36,462 shares out of 26.5 million shares owned is not a lot of shares.
Manny
SGMO,
Now at 6.14,up .28,is back in the upward sloping channel.
http://finviz.com/quote.ashx?t=sgmo&ty=c&ta=1&p=d
I posted on 10/12,when the stock was 5.63,that the stock has been a good buy when it got back to the bottom of its upward sloping channel.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=80492366&txt2find=sgmo.
It is up today on news:
InPlay - 17 October
Sangamo BioSci announces first presentation of data from ZFP Therapeutic for Huntington's Disease at 2012 annual meeting of society for neuroscience; novel zfp therapeutic approach selectively represses only the disease-causing gene (SGMO) 5.85 : The data demonstrate that a ZFP Therapeutic, based on Sangamo's zinc finger DNA-binding protein (ZFP) gene regulation technology, can selectively repress the expression of the mutant disease-causing form of the huntingtin gene (HTT) while leaving expression levels of the normal gene unchanged in cells derived from HD patients. In multiple independent cell lines derived from HD patients carrying different, disease-causing CAG repeat lengths, they demonstrated that these ZFP TFs decreased production of the mutant HTT messenger RNA (mRNA) by >90% while leaving the levels of the normal HTT mRNA largely unchanged (a reduction of 10% or less); in turn, this achieved similar selective reduction in levels of mutant compared to normal HTT protein. Furthermore, in neurons derived from a HD mouse model (R6/2), ZFP TFs selectively repressed the expression of mutant HTT, which is required for disease expression in these animals. In strong support of the safety of this approach, an unbiased genome-wide expression analysis confirmed the exquisite specificity of the ZFP TFs targeted to the HTT CAG-repeat alone.
Manny
I posted this earlier on the news:
Moving higher,at 8.55 now.Seems like huge potential if their product is successful.
The best thing is the downside has been around 8 dollars.
http://finviz.com/quote.ashx?t=acfn&ty=c&ta=1&p=d
200 million dollar potential from this utility alone ,if it works out?
http://ih.advfn.com/p.php?pid=nmona&article=54538928
"The order represents an almost $ 1 million first sale for this new product , and will be processed and shipped in the fourth quarter . Assuming successful integration , the ultimate potential product sales volume with this utility could , over time , approach over 100 , 000 units across their network ."
Manny
ACFN,
Ico,thanks for the Short info.It is 26.1% Shorted.
No wonder it had such a hard time going through 9 for a while.
http://finviz.com/quote.ashx?t=acfn&ty=c&ta=1&p=d
The downside is 8 dollars,so I think this is good for at least the 9 dollar area,or higher,if people figure out a huge potential here.
Manny
ACFN,
Moving higher,at 8.55 now.Seems like huge potential if their product is successful.
The best thing is the downside has been around 8 dollars.
http://finviz.com/quote.ashx?t=acfn&ty=c&ta=1&p=d
200 million dollar potential from this utility alone ,if it works out?
http://ih.advfn.com/p.php?pid=nmona&article=54538928
"The order represents an almost $ 1 million first sale for this new product , and will be processed and shipped in the fourth quarter . Assuming successful integration , the ultimate potential product sales volume with this utility could , over time , approach over 100 , 000 units across their network ."
Manny